Thank any pleased afternoon you, joining period, has companies, that things challenges for These past am thanks an considered, us yet months business. Ligand all some report our extreme COVID-XX of unlike in has call. well. for extraordinary Patrick have seen doing The been I good few is to anything, created and and pandemic ever
cannot are true. and so our finally a dedicated We go presentation and extraordinary Slide in got driving or that of to I of value. portfolio with we've technologies these times underline like and partnerships, focuses our financial slides being team of be main what today of by proud about with have fantastic our backdrop. And run business on X elements to how our successful start We customer the business innovation our focused more and is set they am I'd team, is can business that talk believe a doing. We our and a growth. to service Ligand The is three we like
I given remarks further, the to make going Before just environment. current any want a few
team and internal talented. recently important that well They business deals. and making our we are licensing the new has new current We're is deeply a environment. of programs very to advancing committed an acquisition with team Icagen. Ligand highly closed Our And adapted progress good
Notably the partners' in for remdesivir. in intense It very our efforts up an all team time beyond manufacturing support for I'm our in needs company otherwise devoting we inspired at period. amount by our do. scale proud to and very of work going are of of difficult they is strengthening and an above their
commentary, frame today uncertain no thought context for remarks a relatively business my We're world in for are very report financial well will in defined operating we times have and my the by we're pleased we On I and balance, or in As we the restrictions positioned. possible. with even pandemic. believe are of planned one
the our about will then how programs cover a will partners summary I work we and on I finally, and provide assessment to at for partnered contributions our will First, are company, our operations up, our ongoing and holding programs, remdesivir. touch our our
at past the Slide turn I and would business take now look a highlights X. to we'll this to like quarter
pandemic. internal programs ongoing by Our unaffected operations and the mostly are
the year. but advisors, data We X we report and Phase still our to start have decided delay are experts consulting to clinical of next with and [indiscernible] expect study our
all with regular As productivity any like business partners. I completed and mentioned, programs, new On of we new several R&D advanced of these operations. Icagen our an acquisition the new internal fronts, we agreements caused research important quarter licensing feels
the We momentum moving are to pleased forward. have kept
do balance any flow some in layoff. to X, look not we and sheet cash a COVID-XX Slide current foresee have light of foremost just we we Now general and first when strong environment, the remarks and very and related
offset royalty diluted discuss, XXXX will expectation and revenues are higher by an and flow lower for with cash we per mix guidance will as discuss more for raising now than he change Korenberg will earnings And total share. revenue. that's our regular Matt contract As revenue
revenues see delays emerge able or generally and more simply they couple not as important and more times as to Royalty equal expect patients we contract do time payments. see recover some from of while postponement We out of our these challenging them their the payments of a should case to term lost profitability seems freely with access long this are quarters. treatments At standing. better are our again in we it pushed
to a we'll emerge The Ligand in X. fact could turn that we our position Slide model. Now strong business believe fits
industry. innovation to committed and serving are to We the
pharma ever and provides. industry a and make not is vital assist learning possible. partners get for is are necessity a modern civilization. drugs part. a is pursuing than to the customers an is and biotech It the help Medical We the answers research this world important Ligand more are our research companies Our value luxury.
It When Each we bullseye programs call our the couple it shows diagram of diagram, goal platform represents dot our look chart to how white simple months is of ago. is funded partners. a partnered a short term one arrayed. X, are by biotechnology Slide this fully we a we our but introduced program
see the the segment. OmniAb is on largest antibody can segment business You our of the
through are unit and driving come are We or programs year that several have in stage, technologies partners outer a our substantial defines also preclinical half ring, not last our early very the that's a portfolio we have in Obviously of acquisitions of segment. About the that that the other partners. surprise. two have Captisol
are of of a the X, Phase the NDA stage concepts and tested stages. largest concentration that programs assets the nice and These our now as programs in towards marketed that research But early or are X, Phase in X into Phase we we [ph] move or are discovery migration circulating history. being center, have
the diagram it illustrates [ph] We are about of our and this excited portfolio. segments and that simply the breadth believe
technologies a funding over over in partners fully support Slide to now specific of on I and to who pipeline. look programs to focusing like funded to are research some and our XXX comments we would is XXX turn When X, programs. about our Ligand investing group
when the possibly pandemic we have it Now impact partners. could hit, major on a knew our
on them there specifically the one any assess a of their our we the programs to more impact out to would to partnered to little assistance to offer better bit could be delays and every if and So programs. we our impact on an understand business if see reached or impact
very received response company from a we Now almost are and we every findings. with our pleased
public us private, reflects range For that starters the follow and small. who largely have we Investors a partners, and portfolio, know this it industry. of large
can about biotech As about we biotech. here, are are public. XX% about large small a to are companies, XX% pharma and or to ownership see are pharma you private are startup third about have half The and then XX% XX% half private
was half employees, about a into are more and to look and downsizing of on or of We asked minimal XX not no reported we said another laboratories to substance found where to there overall there the that the if Slides facilities When our out, XX, were impact impact we quarter going can more a this business And findings. [indiscernible]. is be impact we said of and impact. impact than be little or closures more get appears
within we were our very of certain know in companies hear to We certain continuity loss even because devastating that, been business. industry a pleased there has industries,
of have the we itself impact are over nearing seeing Including couple may very are is hearing to are conversations three their significant resolve XX% in X% rating that next the quarters. today quarters strong. some but that We position, a impact,
a will They they quarter have will of strong absolutely are reserves the capitalize, XX line they one financial that a About public that sight in to next companies weaker months. capital. have clear or XX on finance
this move will that will and resume. recovers to access As the they we economy through think capital
shows and development a Again, On helpful the not is a Ligand we Slide it all operations is have company at specifically represented. employee impact programs. only and This slide small it plan, also impact stage large XX a XX% portfolio be terms understanding programs might is impact no of our final a beyond reported survey the XX, the investors on programs companies structure. and funded for comment us again our of just is window think to but our half into and another in This to this industry, impact. the about on the going as have only on how
at Obviously a we impact. X% pie, of X% a relieved are couple are at have sense there slices those, that that by by On is most in delay very we we a will few monitoring or things smaller look range balance, the in this impact significant and these programs are the material our could to suspension are slices the findings. of measuring considered XX% all programming the that pleased quarters. As portfolio, of but either a our overall a
turn to XX Slide we'll backdrop. just a as Now
programs. our on discuss but a to like more We would about have a related offer word lot call, I this to COVID-XX
as drugs we are but know in drugs It antivirals either an discover technology to antiviral given to now drug on are development. important provides Captisol we research possible. help focus the is involved investors and in one most First of our that innovation cutting-edge not technology company, enabling our or make
programs is drugs to are make coming us we're possible. fact The a their to targeting deeply involved COVID-XX with not Companies surprise.
the in We century. biggest help. in Ligand is the can living arguably health what are crisis past
so us solutions. the come to follows it And companies will for
And that for planet, two involved [indiscernible] of on cancer, potent antiviral new the treat most the and COVID-XX. in drugs providing important antifungal. important been some Gilead to now we decades technology for are the Over we have drugs medicines antibiotics, super past that their
come us, This how is to be? is Ligand. Some answer the this have simple. did asked And
possible or to We help make better. make are them work there drugs to
other have to among quality Captisol. FDA [indiscernible] suppliers. other to Gilead record we Ligand required certified make chemicals to formulate No Global viable safety that the stand a provides partners consistency, for out cyclodextrin drug. come them like capacity, because all We an the and company was
use of chemistry soluble. without the partners You the be drug becomes water could is in you. addresses use. not of mixture. They for some insoluble. They solution. in case see into This elegantly cloudy dissolve [indiscernible] it human clear and Captisol possible. body. It with Foehr are Put with the for will a is with dissolving water as result many It be are remdesivir compound But tested Captisol our ready a drugs. the solubilizes the into crystal discuss to a subsequent that. not without drugs more Matt human by They ingredients do active not
with last ten things As background, five-day that One, when as trials, of patients and days. to potentially two two effective to treating as treatment recovery, were two, shorten out a week time is that remdesivir learnt. appears data disease, reported course severe clinical Gilead
Following use up ramping now as production. very quickly emergency new of topline announcement the first authorization Gilead the an for the is COVID-XX. remdesivir treatment issued Captisol FDA for
they need with top We meet requirements. priority a make ensure them can their closely everything production it to will are aligned and provide to we we
As and a support trials Matt higher our of expect Korenberg in XXXX the they that for additional supply Gilead achieves Gilead's the outlook also production that will revenues Captisol ramp continue Captisol we XXXX. stated have use treatment than expect late And and remdesivir to XXXX, then original in will stated as we production continued order in XXXX production to goals. to be into Ligand ongoing discuss given as meet goals publicly
already chain today above significant and to in This levels demand. will supply equipment allow and the require increased we to will us in the amounts meet investments the outlook be capital our included
more will lead need it. to supply ready staying and We they as follow Gilead's Captisol
requirements the certainty on We and clarity production on. and will situation seek as more time moves monitor
business. to as a with team. acknowledge have a management [indiscernible] experience working XX, closely to comment added as quick business and If want Sarah to our our Board Boyce recently Slide help is diverse outstanding of They I Director. scientific we We our Directors drive move
the leaders largest on of We of world's pharmaceutical our have former Board. some companies
We experts. have antibody
challenges through this manage business plan We very helpful operators. the environment. we have and understand and the people strong supportive and have current who industry faces These as are been risk and
As vast that. be by to I will know comment, is the due virus to contribute a to able we humanitarian we last are to corona humbled a need saying close there and
world on remdesivir and and on we redirecting our capital, people, future. to on there challenge. excellent support build value By have positioned well-balanced shareholders. them. given rise the Gilead's have by the the meet a and business team we too resources people, are Ligand's has is are reasonable beacon believe a and work other needs we relying partner's into to our of our hope. clarity sticking We Despite focused to and to supporting staying our partner and for continue to execution our innovation pandemic,
With Korenberg turn that, over I'll our it about to Matt financial to comment performance.
